<i>Background and Objectives:</i> Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as key agents in the management of type 2 diabetes mellitus (T2DM), with expanding indications in heart failure and chronic kidney disease. This evidence concerns the gene SLC5A2 and heart failure.